GlassScriptPhysician profile
David Zarian
NPI 1629179288
$17,578.88
in general payments reported to CMS, 2019-2025
53 companies · $3,102 in 2025
The $3,102 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,994 · 2020: $1,941 · 2021: $2,955 · 2022: $2,800 · 2023: $2,566 · 2024: $2,220 · 2025: $3,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,888.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,900.91 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $1,766.82 | 2019-2025 | Creon, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,765.36 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $1,314.00 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $1,201.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novo Nordisk INC | $938.24 | 2020-2025 | Rybelsus, Ozempic, Saxenda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $907.93 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $661.85 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.65 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Lilly USA, LLC | $495.62 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $416.97 | 2019-2025 | |
| Ardelyx, INC. | $413.62 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $400.64 | 2019-2024 | Trintellix |
| Ironwood Pharmaceuticals, INC | $323.84 | 2020-2024 | Linzess |
| Amarin Pharma, INC. | $321.75 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zarian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.